A Phase II miss for CinCor Pharma (Nasdaq: CINC) has sent the firm’s stock falling precipitously. Shares are now changing hands for around $14, 45% lower than last week.
The drop comes after top-line results were announced following the completion of the HALO trial of baxdrostat, a novel small molecule which blocks the aldosterone synthase enzyme.
CinCor is testing the candidate as an option for people with uncontrolled hypertension taking up to two blood pressure medications at the maximally tolerated doses.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze